Sai Life Science surges 8% in two days; stock hits new high in weak market

▤ Summary

Sai Life Science shares rose sharply as investors reacted to its strong business outlook and sector tailwinds. The company operates in contract research, development, and manufacturing for pharmaceutical and biotechnology customers. Management highlighted strong RFP inflows, high order-book visibility, and more than 90% coverage of its FY27 revenue target through existing orders. The article also points to expansion plans, including a peptide development lab coming online soon and a greenfield peptide manufacturing facility planned for FY28.

▦ Linked Companies